Results 241 to 250 of about 96,820 (286)
Some of the next articles are maybe not open access.
Finasteride: A slow-binding 5.alpha.-reductase inhibitor
Biochemistry, 1993A microsomal preparation of human prostatic tissue was used to study the kinetics of interaction of steroid 5 alpha-reductase with finasteride, a known 5 alpha-reductase inhibitor. This molecule has been reported to reversibly bind 5 alpha-reductase in a competitive manner to testosterone with a Ki value in the 10 nM range.
B, Faller, D, Farley, H, Nick
openaire +2 more sources
Finasteride: the first 5 alpha-reductase inhibitor.
Pharmacotherapy, 1993Finasteride is a synthetic 4-azasteroid that is a specific competitive inhibitor of 5 alpha-reductase, an intracellular enzyme that converts testosterone to dihydrotestosterone (DHT). It has no binding affinity for androgen receptor sites and itself possesses no androgenic, antiandrogenic, or other steroid hormone-related properties.
S L, Sudduth, M J, Koronkowski
openaire +2 more sources
5‐Alpha reductase inhibitor related litigation: A legal database review
Andrology, 2021AbstractBackground5α‐reductase inhibitors are commonly prescribed medications with multiple side effects used in the treatment of male pattern hair loss and benign prostatic hyperplasia. These side effects including “post‐finasteride syndrome” may result in lawsuits.ObjectivesTo characterize lawsuits involving the adverse side effects of 5α‐reductase ...
Patrick Low +7 more
openaire +3 more sources
Azasteroids as inhibitors of rat prostatic 5.alpha.-reductase
Journal of Medicinal Chemistry, 1984A series of A-ring heterocyclic steroids has been prepared and tested for inhibition of rat prostatic steroid 5 alpha-reductase in vitro. Strikingly high inhibitory activity was found with a group of 17 beta-substituted 4-methyl-4-aza-5 alpha-androstan-3-ones. These compounds were prepared from 3-keto-delta 4-precursors by oxidative (O3 or NaIO4-KMnO4)
G H, Rasmusson +6 more
openaire +2 more sources
5-Alpha-reductase inhibitors in diseases of the prostate
Current Opinion in Endocrinology, Diabetes & Obesity, 2014To summarize the history of the use of 5-alpha-reductase inhibitors in the treatment of urologic diseases and discuss the current practices and indications for therapy.5-Alpha-reductase inhibitors (5-ARIs) are indicated in the treatment of benign prostatic hyperplasia (BPH) with obstructive urinary symptoms to reduce symptoms, reduce the risk of acute ...
Robert J, Carrasquillo +2 more
openaire +2 more sources
[5-alpha-reductase inhibitors].
Acta urologica Belgica, 1995A reflection is made, on the one hand, on the lack of correlation between the intensity of micturition problems and the volume of the prostate and, on the other hand, on the different therapeutic approaches of irritative or obstructive voiding problems, and finally on the insufficiently convincing activity of Finasteride.
K, De Jaegher, P, Kozyreff, H, Claes
openaire +1 more source
Pharmacotherapy of benign prostatic hyperplasia: Inhibitor of 5 alpha-reductase
International Urology and Nephrology, 1997We studied the effects of 5 alpha-reductase inhibitor (finasteride) in the treatment of benign prostatic hyperplasia (BPH). This study is a randomized controlled trial. Sixty-two patients were treated with 5 alpha-reductase (finasteride 5 mg/day) and 61 patients (control group) with placebo for one year.
BAYRAKTAR, YILMAZ +4 more
openaire +3 more sources
Prostate cancer prevention with 5-alpha reductase inhibitors
Current Opinion in Urology, 2018We review the concepts surrounding prostate cancer prevention strategies with 5-alpha reductase inhibitors (5-ARIs) and the controversies associated with their use.Updated data have shown no increased risk of death from the diagnosis of higher risk cancer; however, 5-ARIs remain controversial and not approved for prostate cancer prevention.The main ...
Michael A, Liss, Ian M, Thompson
openaire +2 more sources
Novel aromatase and 5α-reductase inhibitors
The Journal of Steroid Biochemistry and Molecular Biology, 1994Inhibitors of aromatase and 5 alpha-reductase may be of use for the therapy of postmenopausal breast cancer and benign prostatic hyperplasia, respectively. FCE 27993 is a novel steroidal irreversible aromatase inhibitor structurally related to exemestane (FCE 24304).
E, Di Salle +7 more
openaire +2 more sources
5-alpha-reductase inhibitors for prostate cancer prevention
Cochrane Database of Systematic Reviews, 2008Background Five-alpha-reductase inhibitors (5ARI) are frequently used to treat bothersome lower urinary tract symptoms associated with benign prostatic hyperplasia and male androgenic alopecia. They have potential as chemopreventive agents. Objectives We sought to estimate the effectiveness and harms of 5ARI in preventing prostate cancer ...
Timothy J Wilt +4 more
openaire +1 more source